Ibrutinib Yields Response in Patients With Chronic GVHD

Chronic graft vs host disease (GVHD) is a serious complication of allogeneic stem cell transplantation, and among patients who fail corticosteroids there remains an unmet need for an effective therapy.

In this video, Lori Styles, MD, medical director of Pharmacyclics in Sunnyvale, California, discusses a phase I/II study of ibrutinib in patients with chronic GVHD who failed corticosteroids.

Results of the trial (abstract LBA-3) were presented at the 58^th Annual Meeting of the American Society of Hematology, held December 3–6 in San Diego, California.